全文获取类型
收费全文 | 3254篇 |
免费 | 337篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 39篇 |
儿科学 | 186篇 |
妇产科学 | 51篇 |
基础医学 | 366篇 |
口腔科学 | 62篇 |
临床医学 | 359篇 |
内科学 | 690篇 |
皮肤病学 | 88篇 |
神经病学 | 186篇 |
特种医学 | 311篇 |
外科学 | 424篇 |
综合类 | 98篇 |
一般理论 | 1篇 |
预防医学 | 297篇 |
眼科学 | 66篇 |
药学 | 230篇 |
中国医学 | 5篇 |
肿瘤学 | 155篇 |
出版年
2022年 | 13篇 |
2021年 | 41篇 |
2020年 | 27篇 |
2019年 | 32篇 |
2018年 | 58篇 |
2017年 | 33篇 |
2016年 | 47篇 |
2015年 | 52篇 |
2014年 | 76篇 |
2013年 | 78篇 |
2012年 | 116篇 |
2011年 | 124篇 |
2010年 | 82篇 |
2009年 | 91篇 |
2008年 | 125篇 |
2007年 | 119篇 |
2006年 | 112篇 |
2005年 | 95篇 |
2004年 | 100篇 |
2003年 | 132篇 |
2002年 | 127篇 |
2001年 | 108篇 |
2000年 | 110篇 |
1999年 | 98篇 |
1998年 | 83篇 |
1997年 | 76篇 |
1996年 | 96篇 |
1995年 | 78篇 |
1994年 | 75篇 |
1993年 | 79篇 |
1992年 | 75篇 |
1991年 | 70篇 |
1990年 | 66篇 |
1989年 | 85篇 |
1988年 | 84篇 |
1987年 | 74篇 |
1986年 | 82篇 |
1985年 | 78篇 |
1984年 | 55篇 |
1983年 | 37篇 |
1982年 | 49篇 |
1981年 | 24篇 |
1980年 | 25篇 |
1979年 | 47篇 |
1978年 | 32篇 |
1977年 | 34篇 |
1976年 | 20篇 |
1975年 | 36篇 |
1974年 | 17篇 |
1973年 | 20篇 |
排序方式: 共有3614条查询结果,搜索用时 15 毫秒
1.
2.
3.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
4.
AIM: To assess the efficacy of intravesical botulinum toxin type A (BTX-A) in interstitial cystitis (IC). METHODS: Eleven patients with IC were injected with BTX-A. Primary outcome measures were: Bristol Female Lower Urinary Tract Symptom Score, Kings Health Questionnaire and 24-hour frequency-volume chart. They had urodynamics done before and six weeks after injection. Detrusor contractility was assessed using the modified PIP1 (projected isovolumetric detrusor pressure). 相似文献
5.
An in-vitro study of the interactions between intravenous induction agents and the calcium antagonists verapamil and nifedipine 总被引:1,自引:0,他引:1
Thiopentone, propofol and etomidate inhibit the contractions of the rat isolated atria and portal vein. The actions of thiopentone and propofol summate with those of verapamil and nifedipine. Verapamil potentiates the action of etomidate on both preparations. The depressant actions of thiopentone and propofol on the portal vein are associated with a reduced response to calcium. Etomidate does not reduce the response to calcium in this preparation. 相似文献
6.
7.
A H Filipovich D Vallera P McGlave D Polich K Gajl-Peczalska R Haake L Lasky B Blazar N K Ramsay J Kersey 《Transplantation》1990,50(3):410-415
Twenty-nine patients with advanced leukemias (median age 34 years) received histocompatible sibling marrow that had been depleted of T cells by ex vivo incubation with anti-CD5 monoclonal antibody-ricin immunotoxin (T101-R) for the purpose of graft-versus-host disease prophylaxis. Donor cell engraftment was documented in 28/29 patients by DNA restriction fragment length polymorphisms. In this pilot study the dose of T101-R incubated with donor marrow was increased in a stepwise manner from 300 ng (10 patients) to 600 ng (5 patients) to 1000 ng immunotoxin (IT)/10(7) bone marrow mononuclear cells (14 patients) in an attempt to achieve more effective GvHD prophylaxis. A statistically significant reduction in acute GvHD was achieved for patients receiving marrow pretreated with 1000 ng of immunotoxin (34%) compared to recipients of BM treated with 300 ng immunotoxin (100%, P = 0.0004). T-depleted marrow samples were evaluated for residual T cell activity using several in vitro assays including proliferation to the purified mitogen PHA (HA-17) and in mixed lymphocyte culture (MLC), T cell cytotoxicity, a limiting dilution assay for detecting precursors of proliferating T cells (LDApPTL), and phenotypic analysis of viable T cells expanded in 16-day culture with interleukin 2. The extent of T cell depletion determined by LDA assay varied widely at each immunotoxin concentration used. Thus, there was no correlation between the dose of T cells infused and subsequent GvHD. Phenotyping of lymphocytes recovered from immunotoxin-treated marrow demonstrated that residual T cells were CD5 negative in all cases tested. The only in vitro parameter that predicted subsequent acute or chronic GvHD was the demonstration of viable CD5 negative lymphocytes with T cell phenotype (CD2, CD3, and/or CD7 positive) after 16-day culture with IL-2 of the T-depleted bone marrow. We observed that such CD5 negative cells expressing other T cell markers have cytotoxic function and speculate that these cells may be capable of mediating GvHD in allogeneic transplantation. 相似文献
8.
9.
10.